Beranda › Skizofrenia › Maryland
Uji klinis Skizofrenia di Maryland
18 studi untuk Skizofrenia mencari peserta di lokasi di Maryland.
Kota di Maryland
Teks studi resmi (Bahasa Inggris)
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
- University of Maryland, Baltimore, Baltimore
Menerima pesertaSukarelawan sehat diterima
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07853807Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- The Johns Hopkins Hospital, Baltimore
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07101094Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0192, Gaithersburg
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07686263NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Gaithersburg
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07114874A Study of Brenipatide in Adult Participants With Schizophrenia
- CBH Health, Gaithersburg
Menerima pesertaFase 2
Usia 18 hingga 55 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07410507A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
- CBH Health LLC., dba CenExel Gaithersburg MD, Gaithersburg
Menerima pesertaFase 1
Usia 18 hingga 55 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07734493A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
- Cbh Health - Gaithersburg /ID# 272932, Gaithersburg
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT0714591852-week Open Label Safety-Tolerability Study
- CenExel Gaithersburg, Gaithersburg
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07369154A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Gaithersburg
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07459647A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Cenexel CBH, Gaithersburg
Menerima pesertaFase 2
Usia 18 hingga 55 · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT07191483Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
- University of Maryland School of Medicine, Baltimore
Menerima pesertaFase 4
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT05208190Synbiotic Compound to Reduce Symptoms of Schizophrenia
- Sheppard Pratt Health System, Batlimore
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 7 Apr 2026 · NCT04226898NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Gaithersburg
Menerima pesertaFase 3
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 6 Mar 2026 · NCT06963034White Matter Plasticity in Schizophrenia
- Maryland Psychiatric Research Center, Catonsville
- University of Maryland Baltimore - Maryland Psychiatric Research Center, Catonsville
Menerima peserta
Usia 15 hingga 45 · Semua jenis kelamin · Diperbarui 20 Feb 2026 · NCT06641297TMS for Inhibition Enhancement in Schizophrenia
- Maryland Psychiatric Research Center, Catonsville
Menerima peserta
Usia 18 hingga 45 · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT06155682CBT-CP for Veterans With SMI
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Feb 2026 · NCT06758414Study of ALTO-101 in Patients With Schizophrenia
- Site 5062, Gaithersburg
Menerima pesertaFase 2
Usia 21 hingga 55 · Semua jenis kelamin · Diperbarui 26 Des 2025 · NCT06502964Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Gaithersburg
Menerima pesertaFase 3Sukarelawan sehat diterima
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 19 Des 2024 · NCT05184335Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.